EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by T. Tammela,1 C. Massard,2 P. Bono,3 P. Langmuir,4 J. Aspegren,5 A. Vuorela,5 M.V.J. Mustonen,5 and K. Fizazi2 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU-2014-ODM-201-poster thumb

1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2Institute Gustave Roussy, University of Paris Sud, Dept. of Cancer Medicine, Villejuif, France, 3Helsinki University Hospital, Dept. of Oncology, Helsinki, Finland, 4Endo Pharmaceuticals, Dept. of Clinical Development, Malvern, United States, 5Orion Corporation Orion Pharma, Dept. of Research and Development, Espoo, Finland